Investment Rating - The investment rating for the company is "Recommended" [2][3] Core Views - The report highlights that the Hong Kong Stock Exchange (HKEX) has experienced strong growth in revenue and profit due to a vibrant market environment, with a 37% year-over-year increase in revenue to HKD 23.745 billion and a 36% increase in net profit to HKD 17.754 billion for the fiscal year 2025 [3][6] - The report emphasizes the robust performance across various segments, with trading fees and system usage fees increasing by 44%, settlement and clearing fees by 49%, and listing fees by 21% [6] - The report notes that the average daily trading volume for securities products increased by 93% year-over-year to HKD 231.5 billion, driven by a 27.7% rise in the Hang Seng Index [6] Summary by Relevant Sections Financial Performance - For the fiscal year 2025, the company achieved total revenue of HKD 23.745 billion, a 37% increase year-over-year, and a net profit of HKD 17.754 billion, also up 36% year-over-year [3][6] - The return on equity (ROE) for 2025 was reported at 30.5%, reflecting a 6.3 percentage point increase year-over-year [6] Revenue Breakdown - Revenue from the cash market segment grew by 58%, while revenue from equity securities and financial derivatives increased by 18% [6] - The report indicates that the IPO market was particularly strong, with 119 IPOs raising HKD 645.9 billion, a 236% increase year-over-year [6] Future Projections - Revenue projections for 2026 to 2028 are estimated at HKD 31.273 billion, HKD 32.671 billion, and HKD 34.135 billion, respectively, with corresponding year-over-year growth rates of 7.2%, 4.5%, and 4.5% [5] - The projected net profit for 2026 to 2028 is expected to be HKD 19.087 billion, HKD 20.048 billion, and HKD 21.006 billion, with growth rates of 7.5%, 5.0%, and 4.8% respectively [5][6] Valuation Metrics - The report provides a price-to-earnings (P/E) ratio forecast of 27.8x for 2026, 26.5x for 2027, and 25.3x for 2028, indicating a gradual decline in valuation multiples [5][6] - The price-to-book (P/B) ratio is projected to decrease from 9.1 in 2025 to 8.3 by 2028 [5][6]

Investment Rating - The report maintains a "Buy" rating for the company, 百济神州 (6160 HK) [2][11]. Core Insights - The company demonstrated strong product sales in Q4 2025, with revenue reaching USD 1.476 billion, a year-on-year increase of 32%. The sales of the drug, Zejula, amounted to USD 1.1 billion, with a significant market share in the US [6]. - The company is increasing its R&D investments in 2026, focusing on pipeline development and prioritizing management, which is expected to yield multiple catalysts [2][6]. - The revenue guidance for 2026 is set between RMB 62-64 billion, with a projected non-GAAP net profit of RMB 14-15 billion [6]. Financial Performance - The company’s revenue for 2026 is forecasted at RMB 6,317 million, a decrease of 3% from previous estimates. The gross profit is expected to be RMB 5,564 million, down by 1% [5]. - The gross profit margin is projected to be 88.0%, an increase of 0.9 percentage points compared to previous estimates [5]. - The GAAP net profit for 2026 is estimated at RMB 750 million, reflecting a 15% decrease from prior forecasts [5]. Stock Performance - The stock price closed at HKD 194.40, with a target price adjusted to HKD 229.20, indicating a potential upside of 17.9% [1][11]. - The stock has shown a year-to-date change of 8.42% [4]. Pipeline Development - The company is focusing on four core strategic areas for pipeline development: chronic lymphocytic leukemia (CLL), other hematological malignancies, solid tumors, and inflammation/immune diseases [6]. - Key upcoming milestones include the potential approval of Sotigalimab in the US and Europe, and the initiation of several clinical trials for new therapies [6].

Investment Rating - The report maintains a "Buy" rating for Haidilao (06862.HK) [1] Core Insights - Haidilao is the leading player in the Chinese hot pot industry, with a market share of 6.7% in 2024, and is transitioning from a single hot pot brand to a multi-brand restaurant ecosystem, including various cuisines such as noodles, fried chicken, and grilled fish [14][25] - The company has a stable and concentrated shareholding structure, which enhances decision-making efficiency [20] - The restaurant's revenue is expected to grow steadily, with projected total revenue of 42.97 billion yuan in 2025, reflecting a year-on-year growth of 0.5% [1][25] Summary by Sections 1. Company Overview - Haidilao operates 15 restaurant brands with a total of 1,489 outlets, including 1,363 hot pot restaurants as of mid-2025 [14] - The company has implemented the "Red Pomegranate" strategy to diversify its offerings beyond hot pot, aiming to create a comprehensive dining ecosystem [14] 2. Market Position - The Chinese hot pot market is projected to reach approximately 619.9 billion yuan by 2024, with a compound annual growth rate (CAGR) of 3.6% from 2019 to 2024 [57] - The hot pot segment represents 14.5% of the Chinese cuisine market, making it the largest category within Chinese dining [52] 3. Financial Performance - Revenue for Haidilao is forecasted to be 42.97 billion yuan in 2025, with a net profit of 4.28 billion yuan, reflecting a year-on-year decrease of 9% [1][25] - The average table turnover rate for Haidilao restaurants improved to 4.10 times per day in 2024, up from 3.0 times in 2021 [32] 4. Strategic Initiatives - The company is focusing on prudent store openings, primarily in lower-tier cities, while enhancing the quality and performance of existing outlets [14] - Haidilao has introduced a management model allowing a single manager to oversee multiple locations, thereby reducing operational costs [40]

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 229.20, indicating a potential upside of 17.9% from the current price of HKD 194.40 [1][11]. Core Insights - The company has shown strong sales performance in Q4 2025, particularly with the drug Zebutinib, which achieved sales of USD 1.1 billion, reflecting a year-on-year increase of 38% [6]. - The company is focusing on enhancing its research and development efforts in 2026, with a revenue guidance of USD 6.2 to 6.4 billion and a non-GAAP net profit forecast of USD 1.4 to 1.5 billion [6]. - The company is strategically prioritizing its pipeline development in four key areas: chronic lymphocytic leukemia (CLL), other hematological malignancies, solid tumors, and inflammation/immunology [6]. Financial Performance - For 2026, the company is projected to generate revenue of RMB 6,317 million, with a gross profit of RMB 5,564 million, resulting in a gross margin of 88.0% [5][12]. - The GAAP net profit for 2026 is estimated at RMB 750 million, with a net profit margin of 11.9% [5][12]. - The company’s stock price has shown a year-to-date increase of 8.42% [4]. Market Position - Zebutinib holds approximately 50% market share among BTK inhibitors and about 25% among all treatment options for 1L CLL patients in the U.S. market [6]. - The company is expected to maintain its leading position in the slow-growing lymphoma market, with new drug approvals anticipated in 2026 [6]. Valuation - The DCF valuation model estimates the equity value of the company at approximately USD 45.27 billion, translating to a per-share value of HKD 229.20 [7].

Investment Rating - The report maintains a "Buy" rating for Haidilao (06862.HK) [1] Core Insights - Haidilao is the leading player in the Chinese hot pot industry, with a market share of 6.7% in 2024, and is transitioning from a single hot pot brand to a multi-brand restaurant ecosystem, including various dining categories such as hot pot, noodles, fried chicken, and grilled fish [14][52] - The company has a stable and concentrated shareholding structure, which enhances decision-making efficiency [20] - The restaurant's revenue is primarily driven by its dining operations, which consistently account for over 90% of total revenue from 2021 to 2024 [26] Summary by Sections 1. Business Overview - Haidilao operates 1,489 restaurants under 15 brands, with 1,363 being hot pot outlets as of mid-2025 [14] - The company has implemented a cautious approach to store openings, focusing on enhancing the quality and performance of existing outlets rather than aggressive expansion [32] 2. Market Position - The Chinese restaurant market is expanding, with the market size projected to grow from CNY 3.95 trillion in 2020 to CNY 5.47 trillion by 2024, reflecting a CAGR of 8.5% [44] - The hot pot segment is the largest within Chinese cuisine, accounting for 14.5% of the market share in 2024, and is expected to benefit from increasing consumer spending and dining out frequency [52][59] 3. Financial Performance - Revenue forecasts for Haidilao are adjusted to CNY 429.69 billion, CNY 455.45 billion, and CNY 485.47 billion for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 0.5%, 6.0%, and 6.6% [1] - The net profit attributable to shareholders is projected to be CNY 42.78 billion, CNY 47.48 billion, and CNY 51.65 billion for the same years, with growth rates of -9%, +11%, and +9% [1] 4. Operational Strategies - The company has introduced the "Red Pomegranate" strategy to diversify its restaurant offerings and enhance its brand matrix, which includes various dining formats [14] - Haidilao's average table turnover rate improved to 4.10 times per day in 2024, up from 3.0 times in 2021, indicating a recovery in operational efficiency [32] 5. Cost Management - The proportion of raw material and employee costs relative to total revenue has decreased, with raw material costs at 38% and employee costs at 33% in 2024, down from previous years [40]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 12.91 [1][9]. Core Views - The company reported a revenue of RMB 20.83 billion for 2025, a decrease of 6.7% year-on-year, and a net profit attributable to shareholders of RMB 2.73 billion, down 19.0% year-on-year, but better than the previous expectation of RMB 2.21 billion, mainly due to stable growth in the automotive glass business and effective cost control [5][6]. - The float glass industry is currently at the bottom of the cycle, and a supply-side contraction is needed for supply-demand rebalancing. As a leading float glass company, it has significant scale and cost advantages, which are expected to show substantial profit elasticity during the industry recovery [5][6]. - The automotive glass business has shown resilient growth, with revenue and gross margin both increasing against the trend, providing stable profit support for the company [6][9]. Business Performance - In 2025, the revenue breakdown by business segment was RMB 11.51 billion for float glass, RMB 6.86 billion for automotive glass, and RMB 2.45 billion for architectural glass, with year-on-year changes of -10.8%, +8.8%, and -21.1% respectively [6]. - The gross margins for these segments were 18.0%, 54.1%, and 28.5%, with year-on-year changes of -4.8%, +1.8%, and -3.3 percentage points respectively [6]. - The company's overseas revenue reached RMB 7.52 billion, an increase of 6.3% year-on-year, accounting for 36.1% of total revenue, up 4.4 percentage points year-on-year, driven by the expansion of automotive glass sales overseas and the commissioning of production bases in Indonesia [6][9]. Financial Metrics - The company’s operating cash flow for 2025 was RMB 5.32 billion, a decrease of 4.8% year-on-year, but still maintained a healthy cash flow level during the industry downturn [7]. - The net debt ratio at the end of 2025 was 5.9%, down 11.1 percentage points year-on-year, indicating a robust financial position that supports navigating through the industry cycle [7]. - The forecast for EPS is RMB 0.71 for 2026, RMB 0.80 for 2027, and RMB 0.88 for 2028, reflecting an upward adjustment due to improved overseas business profitability [9][23]. Industry Outlook - The demand side remains weak in the domestic real estate market, but recent measures in cities like Beijing and Shanghai to stabilize the market may lead to marginal improvements in glass demand [8]. - The supply side is experiencing a clear contraction trend, with many float glass companies facing losses, leading to voluntary production cuts. As of the end of February, the domestic float glass daily melting capacity has dropped to 147,000 tons, the lowest in nearly five years [8]. - If the industry capacity continues to shrink, the supply-demand balance is expected to improve, and float glass prices may stabilize and rebound [8].

Investment Rating - The report initiates coverage with a "Buy" rating for Lepu Biopharma (2157.HK) [4] Core Insights - Lepu Biopharma's ADC drug MRG006A has received approval for clinical trials, marking a significant step towards precision treatment for liver cancer [1] - MRG006A is the first GPC3-targeted ADC to enter clinical trials globally, with potential to address unmet clinical needs in liver cancer treatment [1][2] - The company has a strong pipeline with multiple ADC products and has successfully commercialized two drugs, indicating a leading position in the ADC market [3] Financial Projections - Expected revenues for Lepu Biopharma are projected to be 368 million RMB in 2024, 944 million RMB in 2025, and 1.428 billion RMB in 2027, with growth rates of 63.2%, 156.5%, and 44.4% respectively [5] - The net profit attributable to the parent company is forecasted to be -411 million RMB in 2024, -35 million RMB in 2025, and 89 million RMB in 2027, indicating a turnaround by 2027 [5] - Earnings per share (EPS) are expected to improve from -0.23 RMB in 2024 to 0.05 RMB in 2027 [5] Product Pipeline and Market Position - Lepu Biopharma's product pipeline includes 8 clinical candidates, with 6 being ADC products, showcasing a robust focus on innovative therapies [3] - The company has successfully licensed two ADCs internationally, with significant financial agreements, indicating strong market confidence [3] - MRG006A and MRG007 are developed based on the next-generation Hi-TOPi ADC platform, which is expected to enhance the company's value [3]

Investment Rating - The investment rating for the company is "Accumulate" [6] Core Insights - The company's sales significantly recovered in H2 2025, and production guidance for 2026 has been further increased. The decline in performance for 2025 is primarily attributed to pricing, with signs of a bottoming out in performance, and 2026 is expected to see both volume and price increases. The financial statements remain robust [2][10]. Financial Summary - Total revenue for 2025 was AUD 5,949 million, a decrease of 13.3% year-on-year. Net profit was AUD 440 million, down 63.8% year-on-year. The company ended 2025 with a cash balance of AUD 2,043 million, indicating a net cash position. The total dividend for 2025 was AUD 0.182 per share, resulting in a payout ratio of 55% [4][10]. Production and Sales Performance - The company achieved a total coal production of 38.6 million tons in 2025, a year-on-year increase of 5%, reaching the upper limit of the annual guidance. Sales volume was 38.1 million tons, a slight increase of 1% year-on-year. The increase in metallurgical coal sales by 17% was primarily due to higher production from the Yarrabee mine and improved coal quality from the Walker and Hunter Valley mines. H2 2025 sales reached 21.5 million tons, a significant 30% increase quarter-on-quarter [10]. Price and Cost Analysis - The average selling price for the year was AUD 146 per ton, down 17% year-on-year. The average prices for H1 and H2 were AUD 149 and AUD 144 per ton, respectively. The cash operating cost for 2025 was AUD 92 per ton, a decrease of 1% year-on-year. The cost guidance for 2026 is set between AUD 90-98 per ton, reflecting a slight increase due to inflation considerations [10]. Cash Flow and Financial Health - As of the end of the reporting period in 2025, the company reported operating cash flow of AUD 1,257 million, significantly exceeding net profit. The company has maintained a net cash position since 2022, with a net debt-to-equity ratio of zero and cash holdings of AUD 2,100 million [10][11].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 4.55, up from the previous HKD 3.56 [7][5]. Core Insights - The company reported a revenue of RMB 20.86 billion for the year 2025, a decrease of 4.8% year-on-year, and a net profit attributable to shareholders of RMB 845 million, down 16.2% year-on-year, slightly below the forecast of RMB 880 million due to higher-than-expected impairment provisions [1][5]. - The photovoltaic glass industry is currently in a supply-demand adjustment phase, but the company, as an industry leader, is expected to navigate through the cycle due to its scale cost advantages, overseas business expansion, and asset optimization strategies [1][5]. Financial Performance - In 2025, the photovoltaic glass segment generated revenue of RMB 17.83 billion, down 5.3% year-on-year, primarily due to a 9.1% decrease in product prices, although sales volume increased by 4.2% [2][5]. - The gross margin for the photovoltaic glass business improved by 4.4 percentage points to 14.1% due to lower raw material and energy costs [2]. - The company’s financial management is prudent, with financial expenses decreasing by 21.4% year-on-year to RMB 340 million, mainly due to the conversion of foreign currency loans to lower-rate RMB loans [3]. - Operating cash flow reached RMB 5.66 billion, significantly up from RMB 1.24 billion in 2024, driven by improved profitability and reduced inventory [3]. Business Segments - The renewable energy segment achieved revenue of RMB 2.99 billion in 2025, remaining stable year-on-year, as the company paused new photovoltaic power station projects [2]. - The overseas market for photovoltaic glass showed strong performance, with revenue increasing by 36.0% year-on-year, raising its share of total revenue from 23.3% in 2024 to 33.5% in 2025 [2]. Market Outlook - The global photovoltaic installation volume is expected to remain under pressure in 2026 due to policy adjustments in major markets, although short-term export demand is supported by the cancellation of VAT export rebates starting April 1, 2026 [4]. - The company proactively reduced production capacity by halting two domestic production lines in July 2025, which helps manage inventory risks and alleviate price pressures in the industry [4]. Earnings Forecast and Valuation - The report adjusts the earnings forecasts for 2026-2028, projecting EPS of RMB 0.20, RMB 0.24, and RMB 0.28 for those years, reflecting increases of 25% and 31% compared to previous estimates [5][12]. - The company is expected to maintain a long-term value with a target PE of 20 times for 2026, corresponding to a target price of HKD 4.55 [5][12].

Investment Rating - The report assigns a "Buy" rating for Hesai Technology (02525.HK) as it initiates coverage [1]. Core Insights - The report highlights the transition of LiDAR technology from traditional mechanical optical devices to chip-based components, indicating a trend of lower prices and enhanced performance [8]. - The report identifies key drivers for the increasing penetration of LiDAR, including its safety features, the rise of L3 and L4 autonomous vehicles, and the continuous reduction in LiDAR costs [63][64]. - Hesai's strategic decisions are noted for their foresight, having shifted from air quality detection to the LiDAR market, capturing significant market share in the L4 autonomous driving segment [11][81]. Summary by Sections Current LiDAR Industry Characteristics - The LiDAR market is highly concentrated, with the top four suppliers holding over 99% market share as of 2025 [7]. - LiDAR technology is evolving rapidly, with a shift towards chip integration and lower costs, enhancing performance [8][48]. - The report emphasizes the increasing importance of LiDAR as a safety component in vehicles, with projections indicating that L3 vehicles may require 3-6 LiDAR units per vehicle [63]. Market Competition Landscape - The competitive landscape is dominated by major players like Huawei and Hesai, with Hesai's ATX product offering superior performance at comparable prices [77][78]. - The report notes that the LiDAR market is characterized by strong economies of scale, making it difficult for new entrants to compete effectively [77]. Hesai Company Overview - Hesai has transitioned from an air quality detection company to a leading global LiDAR manufacturer, launching several successful products since its inception in 2014 [81][84]. - The company has strategically positioned itself in the automotive market, with significant revenue contributions from its LiDAR products [85]. - The management team is noted for its balanced ownership and strong technical background, contributing to the company's innovative capabilities [11][84]. Long-term Growth Potential and Current Stock Price - The report forecasts significant revenue growth for Hesai, projecting revenues of 34.09 billion, 49.16 billion, and 60.56 billion RMB for 2025, 2026, and 2027 respectively, with corresponding Non-GAAP net profits of 5.05 billion, 6.91 billion, and 9.53 billion RMB [12]. - Given the company's leadership position in a high-growth sector, a price-to-earnings ratio of 50 is applied, resulting in a target market capitalization of 394 billion HKD [12].